Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 75, Issue 5, 2016, Pages 897-905

  Wu, Jashin J ^a   Strober, Bruce E ^b,c   Hansen, Peter R ^d   Ahlehoff, Ole ^e   Egeberg, Alexander ^d   Qureshi, Abrar A ^f,g   Robertson, Debbie ^h   Valdez, Hernan ^h   Tan, Huaming ^h   Wolk, Robert ^h  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e University of Copenhagen   (Denmark)

^f BROWN UNIVERSITY   (United States)

^g BROWN UNIVERSITY   (United States)

^h PFIZER INC   (United States)

Author keywords

cardiovascular outcomes; cardiovascular risk factors; major adverse cardiovascular events psoriasis; tofacitinib

Indexed keywords

C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PLACEBO; TOFACITINIB; CHOLESTEROL; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPOSURE; FEMALE; FOLLOW UP; HEART ARREST; HUMAN; HYPERTENSION; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMORBIDITY; DYSLIPIDEMIAS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84995380101     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.06.012     Document Type: Article

References (35)

1. 1 Parisi, R., Symmons, D.P., Griffiths, C.E., Ashcroft, D.M., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133 (2013), 377–385.
2. 2 Koebnick, C., Black, M.H., Smith, N., et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr 159 (2011), 577–583.
3. 3 Herron, M.D., Hinckley, M., Hoffman, M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005), 1527–1534.
4. 4 Qureshi, A.A., Choi, H.K., Setty, A.R., Curhan, G.C., Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145 (2009), 379–382.
5. 5 Prodanovich, S., Kirsner, R.S., Kravetz, J.D., Ma, F., Martinez, L., Federman, D.G., Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145 (2009), 700–703.
6. 6 Love, T.J., Qureshi, A.A., Karlson, E.W., Gelfand, J.M., Choi, H.K., Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 147 (2011), 419–424.
7. 7 Channual, J., Wu, J.J., Dann, F.J., Effects of TNF-alpha blockade on metabolic syndrome in psoriasis: lessons learned from rheumatoid arthritis and psoriatic arthritis. Dermatol Ther 22 (2009), 61–73.
8. 8 Kaye, J.A., Li, L., Jick, S.S., Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008), 895–902.
9. 9 El-Mongy, S., Fathy, H., Abdelaziz, A., et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol 24 (2010), 661–666.
10. 10 Shapiro, J., Cohen, A.D., David, M., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007), 629–634.
11. 11 Kimball, A.B., Robinson, D. Jr., Wu, Y., et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 217 (2008), 27–37.
12. 12 Gelfand, J.M., Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006), 1735–1741.
13. 13 Gelfand, J.M., Dommasch, E.D., Shin, D.B., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 129 (2009), 2411–2418.
14. 14 Mehta, N.N., Azfar, R.S., Shin, D.B., Neimann, A.L., Troxel, A.B., Gelfand, J.M., Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31 (2010), 1000–1006.
15. 15 van Vollenhoven, R.F., Fleischmann, R., Cohen, S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367 (2012), 508–519.
16. 16 Burmester, G.R., Blanco, R., Charles-Schoeman, C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
17. 17 Lee, E.B., Fleischmann, R., Hall, S., et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370 (2014), 2377–2386.
18. 18 Bissonnette, R., Iversen, L., Sofen, H., et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 172 (2015), 1395–1406.
19. 19 Bachelez, H., van de Kerkhof, P.C., Strohal, R., et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386 (2015), 552–561.
20. 20 Papp, K.A., Menter, M.A., Abe, M., et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two, randomised, placebo-controlled, phase III trials. Br J Dermatol 173 (2015), 949–961.
21. 21 Charles-Schoeman, C., Fleischmann, R., Davignon, J., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 67 (2015), 616–625.
22. 22 Papp, K.A., Menter, A., Strober, B., et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167 (2012), 668–677.
23. 23 Neimann, A.L., Shin, D.B., Wang, X., Margolis, D.J., Troxel, A.B., Gelfand, J.M., Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006), 829–835.
24. 24 Clinical Data Interchange Standards Consortium website. Standardized definitions for cardiovascular and stroke endpoint events in clinical trials. Available at: http://www.cdisc.org/system/files/all/standard/Draft%20Definitions%20for%20CDISC%20August%2020%202014.pdf. Accessed October 28, 2015.
25. 25 Mehta, N.N., Yu, Y., Pinnelas, R., et al. Attributable risk estimate of severe psoriasis on major adverse cardiac events. Am J Med, 124, 2011, 775 e1-6.
26. 26 Ahlehoff, O., Gislason, G.H., Charlot, M., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270 (2011), 147–157.
27. 27 McInnes, I.B., Kim, H.Y., Lee, S.H., et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 73 (2014), 124–131.
28. 28 Choy, E., Sattar, N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68 (2009), 460–469.
29. 29 Toms, T.E., Panoulas, V.F., Douglas, K.M., et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. Angiology 62 (2011), 167–175.
30. 30 Lewington, S., Whitlock, G., Clarke, R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007), 1829–1839.
31. 31 Manninen, V., Tenkanen, L., Koskinen, P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992), 37–45.
32. 32 Jeppesen, J., Hein, H.O., Suadicani, P., Gyntelberg, F., Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 17 (1997), 1114–1120.
33. 33 Castelli, W.P., Anderson, K., Wilson, P.W., Levy, D., Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 2 (1992), 23–28.
34. 34 Wu, J.J., Choi, Y.M., Bebchuk, J.D., Risk of myocardial infarction in psoriasis patients: a retrospective cohort study. J Dermatolog Treat 26 (2015), 230–234.
35. 35 Papp, K., Gottlieb, A.B., Naldi, L., et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14 (2015), 706–714.